Analyst Price Target is $50.17
▲ +170.44% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for KalVista Pharmaceuticals in the last 3 months. The average price target is $50.17, with a high forecast of $61.00 and a low forecast of $32.00. The average price target represents a 170.44% upside from the last price of $18.55.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in KalVista Pharmaceuticals. This Buy consensus rating has held steady for over two years.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.